Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma

Children's Oncology Group

Status: Completed

Conditions: Neuroblastoma

Treatments: Genetic: RNA analysis; Genetic: protein expression analysis; Genetic: proteomic profiling; Other: mass spectrometry; Other: immunohistochemistry staining method; Genetic: western blotting; Other: enzyme-linked immunosorbent assay; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis; Other: liquid chromatography

Study type: Observational

Funder types: NETWORK; NIH

Identifiers

NCT01387724

COG-ANBL11B1 (Other Identifier)

NCI-2011-02862 (Registry Identifier)

ANBL11B1 (Other Identifier)

Details and patient eligibility

About

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies biomarkers in blood and tissue samples from patients with newly diagnosed neuroblastoma.

Full description

OBJECTIVES:

Determine the expression of neuropeptide Y (NPY) and its receptors (Rs) in human neuroblastoma (NB) tissues. Determine whether BDNF/TrkB and TrkAIII stimulate expression of NPY and its Rs. Determine whether NPY mediates BDNF- and TrkAIII-induced NB proliferation and survival. Determine neurotrophins' angiogenic actions. Identify factors released from NB cells upon NPY stimulation (proteomics). Determine whether NPY upregulates expression of the identified proteins in NB and their Rs in endothelial cells (ECs). Test whether inhibition of the identified pathways reduces angiogenic activity of NB-conditioned media. Determine the mechanisms of NYP actions and signaling pathways. Test whether blocking NPY-Y2/Y5 pathway reduces NB growth and vascularization in vivo.

OUTLINE: Archived tumor tissue and serum samples are analyzed for neuropeptide Y and its receptors (Y1, Y2, and Y5) expression, neuroblastoma prognostic factors (MYCN, TrkA, TrkAIII, TrkB, BDNF, and NGF), and angiogenic markers by real-time PCR, IHC, ELISA, radioimmunoassay (RIA), mitogenic assay, caspase 3/7 activity assay, western blots, liquid chromatography, tandem mass spectrometry, proteomic assays, and other assays. Results are then analyzed and compared with patients' clinical data, including stage of disease, its phenotype, prognostic markers, age and gender, and response to treatment.

Enrollment: 300 estimated patients

Sex: All

Ages: 1 to 10 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Children with newly diagnosed neuroblastoma or ganglioneuroblastoma

• Samples from the Children's Oncology Group (COG) from patients enrolled in clinical trials in institutions in the USA, Canada, and Australia

  • Paraffin-embedded tumor specimens, RNA isolated from tumor tissues, and patient serum must be available

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• Not specified